f

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

Steps Ahead: Emerging Therapies in Psoriatic Arthritis

Week 1

Useful Expressions

Tools for Professional Approach: It’s not just about learning, it’s about having the confidence to use English in real life and upgrade your business communication skills.

3 videos, 1 audio, 1 reading
Video: Crowdsourcing
Audio: Listening Exercise
Video: Collocations For Job Interview

Week 2

Diplomatic Language

Tools for Professional Approach - Step 2: It’s not just about learning, it’s about having the confidence to use English in real life and upgrade your business communication skills.

2 videos, 1 audio, 1 reading
Graded: Advanced Business Principles

Steps Ahead: Emerging Therapies in Psoriatic Arthritis

Steps Ahead: Emerging Therapies in Psoriatic Arthritis was a fast-paced workshop featuring real-life scenarios and discussions designed to provide new ideas, answers, and confidence in treating PsA. Through a series of presentations and exercises, attendees covered a range of diagnosis and therapeutic options, opportunities, and outcomes to ultimately gain a deeper understanding on how to better address care gaps and move the treatment of PsA forward.

  • Daniel Furst, MD

    Daniel E. Furst, MD
    Professor of Rheumatology,
    University of Washington School of Medicine
    Seattle, Washington
    David Geffen School of Medicine at UCLA
    Los Angeles, California

  • Linda Grinnell-Merrick, MS, NP-BC

    Linda Grinnell-Merrick, MS, NP-BC
    Nurse Practitioner,
    Division of Allergy, Immunology, and Rheumatology
    University of Rochester Medical Center
    Rochester, New York

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.  Disclosure appear below as there at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interest — unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

Planner (Forefront Collaborative): Christine Tebben

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenters:

  • Daniel E. Furst, MD: grant/research support from AbbVie, Actelion, Amgen, BMS Corbus, NIH, Novartis, Pfizer, Roche/Genentech; consultant for AbbVie, Actelion, Amgen, BMS, Cytori, Novartis, Pfizer, Roche/Genentech; and on the speakers’ bureau of CMC Connect, (McCann Health Company)
  • Linda Grinnell-Merrick, MS, NP-BC: advisory board for AbbVie, Novartis, Pfizer, Horizon; contracted research for Novartis; and on the speakers’ bureau for AbbVie, Celgene, Novartis and Janssen.

Planner (Forefront Collaborative):

  • Lily Zurkovsky, PhD: has personal stock in Teva Pharmaceutical Industries Ltd.

As a result of participation in this educational activity, participants should increase their ability to:

  • Translate evidence-based recommendations and the latest research data related to use of DMARDs in PsA into clinically meaningful information for managing patients with PsA

  • Optimize monitoring for adherence to treatment, achievement of treatment targets, adverse events, and comorbidities in patients with PsA

  • Develop a patient-centered approach to coordination of PsA care between rheumatology and dermatology providers

  • Effectively engage patients with PsA in SDM regarding treatment goals, development of the treatment plan, and treatment modification

Resources

Unless otherwise specifically prohibited, you may temporarily download one copy of the materials for personal, noncommercial use. You may not modify or copy the materials, use them for any commercial purpose or public display (commercial or noncommercial), remove any copyright or other proprietary notations, or transfer the materials to another person or online site.

Activity Information

Target Audience
The target audience was rheumatologists and nurse practitioners and physician assistants who specialize in rheumatology. Other clinicians who treat patients with PsA may have benefited from participation in this educational activity. 

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designated this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 1.2 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course. 

This activity was approved for 1.00 contact hour(s) of continuing education (which includes 0.50 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 18083318.  This activity was planned in accordance with AANP CE Standards and Policies. 

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly. 

The content of this activity was independently peer reviewed. The reviewers of this activity had no relevant financial relationships to disclose. 

This continuing medical education activity may have included reference(s) to unlabeled or unapproved uses of drugs.  

Provider
This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.